Abstract 5818: Features of cancer cachexia in non-small cell lung cancer: Insights from the prospective TRACERx study

• Published in: Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.5818-5818
• Main Authors: Al-Sawaf, Othman, Skrzypski, Marcin, Weiss, Jakob, Karasaki, Takahiro, Birkbak, Nicolai Juul, Zambrana, Francisco, Frankell, Alexander, Watkins, Thomas B., Ruiz, Carlos Martinez, Veeriah, Selvaraju, Naceur-Lombardelli, Cristina, McGranahan, Nicholas, Aerts, Hugo, Swanton, Charles, Jamal-Hanjani, Mariam
• Format: Article
• Language: English
• ISSN: 1538-7445; 1538-7445
• DOI: 10.1158/1538-7445.AM2022-5818

Introduction: Cancer cachexia (CC) is a major contributor to morbidity and mortality in patients with non-small cell lung cancer (NSCLC). It is characterized by loss of skeletal muscle (SM) tissue with or without adipose tissue loss. This analysis reports on the characteristics and outcomes of patients recruited into the prospective TRACERx study, who presented with or subsequently developed features of CC during follow-up. Approach: Using longitudinal CT imaging, total, subcutaneous and visceral adipose tissue (TAT, SAT, VAT) and SM volumes were manually quantified at the 3rd lumbar vertebrae level. Body weight was measured every 3-6 months and grouped according to BMI-adjusted weight loss grades. Multi-region primary tumour tissue was collected at the time of surgical resection and subjected to whole exome and RNA sequencing. Results: Patients in the TRACERx 421 cohort who presented with low SAT volume at diagnosis, represented by the lower 20% percentile of the cohort, had significantly shorter lung-cancer specific survival (LCSS) and overall survival (OS) compared with patients in the 80% percentile (3-y LCSS 61% vs 81%, p